CFOROTCServices-Medical LaboratoriesFiscal year ends December 31
CapForce Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$4.03+0.53 (+15.14%)
Close on Oct 19, 2026
- Market cap
- $50.33M
- P/E (TTM)
- 0.7
- Dividend yield
- –
CapForce Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q4 25 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q3 22 | TTM Q2 22 | TTM Q1 22 | TTM Q4 21 | TTM Q3 21 | TTM Q2 21 | % of revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Listing sponsorship services [Member] | $30.20M | – | – | – | – | – | – | – | – | – | – | – | 100.0% |
| Product [Member] | – | $2.40M | $1.69M | $1.49M | $1.94M | $1.89M | $2.79M | $3.08M | $2.50M | $2.66M | $2.70M | $2.66M | – |
| Service [Member] | – | $153.72K | $190.93K | $174.81K | $151.38K | $172.63K | $264.12K | $425.86K | $672.07K | $813.21K | $586.12K | $506.25K | – |
| Collaboration revenue [Member] | – | $864.55K | $1.19M | $1.16M | $960.91K | $540.80K | $255.27K | $599.18K | $778.84K | $836.15K | $946.53K | $886.35K | – |
By region
| Revenue | TTM Q4 25 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q3 22 | TTM Q2 22 | TTM Q1 22 | TTM Q4 21 | TTM Q3 21 | TTM Q2 21 | % of revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International [Member] | $30.20M | $2.74M | $2.44M | $2.20M | $2.57M | $2.09M | $2.73M | $3.28M | $2.94M | $3.10M | $2.50M | $2.38M | 100.0% |
| Domestic [Member] | – | $678.09K | $628.67K | $621.81K | $479.15K | $520.61K | $583.01K | $820.06K | $1.00M | $1.20M | $1.74M | $1.67M | – |
From the segment and revenue-disaggregation notes of CapForce's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.